• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

GMP manufacture of Shigella flexneri 2a Artificial Invaplex (Invaplex < sub > AR < /sub > ) and evaluation in a Phase 1 Open-label, dose escalating study administered intranasally to healthy, adult volunteers
Vaccine. 2023 Sep 2:S0264-410X(23)00995-7. doi: 10.1016/j.vaccine.2023.08.051. Online ahead of print.ABSTRACTShigella species cause severe disease among travelers to, and children living in, endemic countries. Although significant efforts have been made to improve sanitation, increased antibiotic resistance and other factors suggest an effective vaccine is a critical need. Artificial Invaplex (InvaplexAR) is a subunit vaccine approach complexing Shigella LPS with invasion plasmid antigens. In pre-clinical studies, the InvaplexAR vaccine demonstrated increased immunogenicity as compared to the first generation product and w...
Source: Vaccine - September 4, 2023 Category: Allergy & Immunology Authors: Christopher Duplessis Kristen A Clarkson K Ross Turbyfill Ashley N Alcala Ramiro Gutierrez Mark S Riddle Tida Lee Kristopher Paolino Hailey P Weerts Amanda Lynen Edwin V Oaks Chad K Porter Robert Kaminski Source Type: research

A subtractive proteomics and immunoinformatics approach towards designing a potential multi-epitope vaccine against pathogenic Listeriamonocytogenes
Microb Pathog. 2022 Sep 20:105782. doi: 10.1016/j.micpath.2022.105782. Online ahead of print.ABSTRACTListeria monocytogenes is the causative agent of listeriosis, which is dangerous for pregnant women, the elderly or individuals with a weakened immune system. Individuals with leukaemia, cancer, HIV/AIDS, kidney transplant and steroid therapy suffer from immunological damage are menaced. World Health Organization (WHO) reports that human listeriosis has a high mortality rate of 20-30% every year. To date, no vaccine is available to treat listeriosis. Thereby, it is high time to design novel vaccines against L. monocytogenes...
Source: Cancer Control - September 23, 2022 Category: Cancer & Oncology Authors: Shakilur Rahman Amit Kumar Das Source Type: research

What Do Hospitalists Need to Know About Monkeypox?
What is monkeypox? Monkeypox is a rare infection caused by the monkeypox virus. Monkeypox virus belongs to the Orthopoxvirus genus in the family Poxviridae. The Orthopoxvirus genus also includes variola virus (which causes smallpox), vaccinia virus (used in the smallpox vaccine), and cowpox virus.1 It was first isolated in 1958 and identified as causing human disease in 1970. This pathogen was endemic in central and western African countries up until recently. Between 2018 to May 2022, about nine cases of monkeypox were confirmed in a few non-endemic countries.2 There are two strains of monkeypox: West African monkeypox ...
Source: The Hospitalist - June 24, 2022 Category: Hospital Management Authors: Daniel Hickman Tags: Clinical Guidelines Diagnostic Emerging Infections Infectious Diseases Source Type: research

Modeling Streptococcus pyogenes Pharyngeal Colonization in the Mouse
In conclusion, the mouse pharyngeal colonization model is an affordable and accessible experimental system that allows a broader group of research groups to test the importance of their findings in an in vivo model. There is a great deal of overlap between the bacterial and immune factors found to be important in human and murine pharyngeal colonization. Although MHC-II humanized mice could prove useful in answering certain questions, the use of inbred mouse lines appears to be sufficient for evaluation of most questions, both related to bacterial factors and the host immune response. However, when promising treatments or ...
Source: Frontiers in cellular and infection microbiology - May 1, 2019 Category: Microbiology Source Type: research